Compare iShares MSCI Canada (TSX) (EWC) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs Summit Therapeutics Inc — how do they compare? iShares MSCI Canada (TSX) trades at $59.34, while Summit Therapeutics Inc trades at $13.66 (market cap $11.70B). The key difference: iShares MSCI Canada (TSX) is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| EWC | SMMT | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $59.49 | $29.32 |
52-Week Low | $45.86 | $13.05 |
Market Cap | — | $11.70B |
Enterprise Value | — | $11.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC trades at $59.32, up 0.24% today, with a bullish technical signal driven by moving averages but caution from overbought RSI levels. The stock shows strong support at $59 and resistance at $60. Recent corporate actions include a dividend scheduled for June 2026, while financial ratios are unavailable in the current data.
The outlook for EWC is mixed, with technical strength offset by overbought conditions. Investment opportunities hinge on sustained bullish momentum above $60, but risks include potential pullbacks from current highs and reliance on broader market trends given limited fundamental data.
Summit Therapeutics (SMMT) trades at $13.90, down 10.15% today, reflecting market reaction to mixed earnings and high volatility. The technical picture is bearish with weak moving averages, while fundamentals show significant losses with a net income of -$1.08B in 2025 and negative ROE/ROA. Recent news includes a $105M divestiture of ridinilazole to Biossil, sharpening focus on oncology, and upcoming Q2 2026 results on July 23, 2026.
Outlook hinges on clinical success of ivonescimab, with a bullish analyst consensus (66.7% buy ratings) and $15.57 price target suggesting 12% upside. Key risks include binary drug trial outcomes, cash burn from negative operating cash flow, and high short interest creating volatility. Investors face a high-risk, catalyst-driven opportunity dependent on pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
